MedTrace Logo

Docetaxel (Taxotere) and Imatinib Mesylate (Gleevec) in Hormone Refractory Prostate Cancer

NCT00861471 · Status: TERMINATED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2016-06-30

Study results available
· View outcomes & findings →

Summary

This trial is designed to determine the proper doses of Docetaxel and Imatinib mesylate to be used to treat hormone refractory prostate cancer and to evaluate the safety and efficacy of the treatment.

Conditions

Interventions

DRUG

Docetaxel

One treatment cycle is defined as 21 days. Docetaxel: 70 mg/m\^2 (60 mg/m\^2 was tested in Phase I as well), Intravenous, every 21 days.

DRUG

Imatinib Mesylate

One treatment cycle is defined as 21 days. Imatinib Mesylate: 24-36 hours after Docetaxel, 600 mg (400 mg was tested in Phase I as well), orally, daily x 14 days.

Sponsors & Collaborators

Principal Investigators

  • Anna Ferrari, MD · New York University Cancer Institute

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-05-31
Primary Completion
2010-05-31
Completion
2010-05-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00861471 on ClinicalTrials.gov